Investor

Tap into the exponential growth of RNA-enabled precision neurology

Shifting focus from R&D to Business Development

FBB Biomed's presentation at the Loyal VC Portfolio Showcase (October 2024).

Note that the fundraising terms have been updated in December 2024. For more information, get in touch.

It's easier to just be first

We founded FBB Biomed because we saw the potential of RNA for medicine. COVID-19 made that potential evident to everyone.

Effective therapies only emerge after effective diagnostics. Case in point: drugs for HIV/AIDS. FBB Biomed's technology platform will be the first to enable personalized diagnostics and therapeutics based on ancestral genes.

IP that covers multiple major chronic diseases

Our discovery has a wide range of applications in human, veterinary, and agricultural health markets. Our IP contains data on multiple neurologic, cancer, and autoimmune diseases, including the early detection of disease in asymptomatic individuals.

Product

Company profile

U.S. Veteran-owned
Delaware C corporation
Operating out of Iowa
Supported by the State of Iowa
Loyal VC portfolio company

Awards & Recognition

FBB CEO wins award "Innovator of the Year"

Link

FBB wins 1st place: Iowa Innovation Challenge

Link

FBB featured by ADLM (previously AACC)

Link

FBB wins Iowa JPEC pitch competition

Link

Proprietary AI-powered RNA platform

RNA's abundance in human tissue makes it the ideal foundation for early-stage, highly accurate, truly personalized diagnostics.

Owing to its functional and regulatory role in molecular processes, RNA makes real-time diagnostics possible, as opposed to mere risk stratification.

By leveraging existing genomic sequencing infrastructure and the latest bioinformatics software, we have built a proprietary AI-powered RNA platform with diagnostic as well as therapeutic applications.

Science

Review FBB Biomed investor materials